When regular palliative options fail, the present case series demonstrate that patients with sufficient tumour targeting on 68Ga-PSMA-PET/CT can be treated with PSMA-targeted radioligand therapy using 177Lu-PSMA, that may result in temporary radiological disease stabilization and relief of tumour-related discomfort. The gene discussed is FOLH1; the disease is neoplasm.